InvestorsHub Logo
Followers 4
Posts 1277
Boards Moderated 0
Alias Born 07/14/2008

Re: None

Thursday, 09/11/2014 7:33:48 PM

Thursday, September 11, 2014 7:33:48 PM

Post# of 8299
Well, here it is. Clinical trials are OVER.

September 11, 2014, 5:30 pm EDT

Oxygen Biotherapeutics Announces Halt of Oxycyte Phase IIb Traumatic Brain Injury Trial
MORRISVILLE, N.C.--(BUSINESS WIRE)--Oxygen Biotherapeutics, Inc. (NASDAQ: OXBT), a specialty pharmaceutical company focused on developing and commercializing a portfolio of products for the critical care market, today announced that the Company, with unanimous approval from the Board of Directors, has elected to stop the current Phase IIb trial for its Oxycyte drug candidate and consider strategic alternatives for the program moving forward. The company will review the data generated on the patients enrolled in the trial to date.

Ah, the smell of salt air
and the touch of gentle winds.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent TENX News